Pink Sheet Executive Editor Derrick Gingery, Senior Writer Sarah Karlin-Smith and Interim Editor in Chief Nielsen Hobbs take a deep dive into the US Food and Drug Administration’s new clinical trial diversity action plan draft guidance and consider what information stakeholders may still want (:35), as well as discuss the agency’s plan to issue guidance on artificial intelligence use in regulatory decision-making (27:30).
More On These Topics From The Pink Sheet
- Diversity Action Plans Should Be Brief And Waiver Requests Filed Early, US FDA Says
- Diversity Enrichment: US FDA Guidance Suggests Sponsors May Need To Overenroll Key Groups
- US FDA Guidance On Artificial Intelligence For Regulatory Decision-Making Expected This Year
This and other podcasts are available on the Pink Sheetpodcast page, as well as the Citeline channel on Apple Podcasts, Google Podcasts, SoundCloud, TuneIn and Spotify Podcasts, and via smart speakers if one of these platforms has been set up as your default podcast provider.
